Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 13Thoracic 3Gastrointestinal 2Sarcoma 1NET 1Head & Neck 1Endocrine 1CNS 1

Conditions

Pancreatic Neoplasms 70Colorectal Neoplasms 18Carcinoma, Hepatocellular 17Rectal Neoplasms 13Colonic Neoplasms 13Neoplasm Metastasis 12Esophageal Neoplasms 11Neoplasms 9Gallbladder Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Bile Duct Neoplasms 7Liver Neoplasms 6Adenocarcinoma Of Esophagus 5Breast Neoplasms 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Salivary Gland Neoplasms 3Prostatic Neoplasms 3Gastrointestinal Neoplasms 3Esthesioneuroblastoma, Olfactory 3Esophageal Squamous Cell Carcinoma 3Cholangiocarcinoma 3Urinary Bladder Neoplasms 2Pancreatic Intraductal Neoplasms 2Lung Neoplasms 2Gastrointestinal Stromal Tumors 2Carcinoma, Renal Cell 2Biliary Tract Neoplasms 2Anus Neoplasms 2Adenomatous Polyposis Coli 2

Interventions

pembrolizumab 43Nivolumab 29atezolizumab 11Specimen Handling 10Cyclophosphamide 10Bevacizumab 10Paclitaxel 9Magnetic Resonance Spectroscopy 9cabozantinib 7Ipilimumab 7Carboplatin 7fludarabine 6durvalumab 6avelumab 6Sunitinib 6Sorafenib 6Oxaliplatin 6Fluorouracil 6Docetaxel 6spartalizumab 5sargramostim 5Leucovorin 5Cisplatin 5Cetuximab 5aldesleukin 4Trastuzumab 4Radiosurgery 4Psychiatric Rehabilitation 4Irinotecan 4Gemcitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Erlotinib Hydrochloride × Gastrointestinal × Clear all
NCT01402089 2016-02-02

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Cantonal Hospital of St. Gallen

Phase 4 Completed
54 enrolled
GastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Gastrointestinal Stromal Tumors

NCT00101348 2014-06-11

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
66 enrolled
CNSGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡